Spindletop Health Acquisition Corp.

Spindletop Health Acquisition Corp.

SHCAU
Spindletop Health Acquisition Corp.US flagNASDAQ Global Market
10.12
USD
-0.13
- -
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChat
CEO
Evan S. Melrose
Sector
Financial Services
Industry
Shell Companies
Address
3571 Far West Boulevard Austin TX United States of America 78731
Business
Spindletop Health Acquisition Corp. (SHCAU) is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, with a focus on the healthcare services industry sector, including healthcare services, healthcare information technology, insurance and related products, biotechnology, pharmaceuticals, medical devices, and diagnostics. Incorporated on February 17, 2021, as a Delaware corporation and headquartered in Austin, Texas, the company has no significant current operations and generates no revenues. The company completed a $230 million initial public offering in November 2021, with units listed on Nasdaq under the ticker SHCAU, led by CEO and Director Dr. Evan S. Melrose, COO Dr. Kelly Huang, and Chairman James Henry. In a major development, Spindletop Health Acquisition Corp. announced its liquidation and dissolution in December 2022 after failing to identify a suitable acquisition target by the board-set termination date of December 20, 2022, opting not to implement a stockholder-approved extension; public shares were redeemed by December 27, 2022. The company conducted its search primarily in the United States healthcare ecosystem but ceased operations without completing any mergers, partnerships, or strategic shifts.